Abstract
There is an urgent need for low-cost and simple-to-use tools for identifying substandard and falsified medicines. In this work we demonstrate “Disintegration Fingerprinting” (DF), a technique that identifies pills, tablets, caplets, and other solid-dosage drugs based on how the drug disintegrates and dissolves in liquid. The DF hardware consists of a water-filled transparent plastic cup atop a conventional magnetic stirrer. An inexpensive sensor mounted on the outside of the cup shines infrared light into the cup and measures the amount of light that is reflected back to the sensor. When a pill is added to the stirred water, the pill begins to disintegrate into particles that swirl around inside the cup. Whenever one of these particles passes near the infrared sensor, the particle reflects additional light back to the sensor and creates a millisecond-duration peak in a plot of sensor output vs. time. The number of particles in the water changes over time as the particles continue to disintegrate and (in some cases) eventually dissolve away. By plotting the number of particles detected vs. time, we create a Disintegration Fingerprint that can be used to identify the drug product. In a proof-of-concept study, we used DF to analyze 96 pills from 32 different drug products (including antibiotics, opioid and non-opioid analgesics, antidepressants, anti-inflammatories, antiemetics, antihistamines, decongestants, muscle relaxants, expectorants, sleep aids, cold medicines, antacids, hormonal birth control, and dietary supplements, as well as a simulated falsified drug product). We found that DF correctly identified 90% of these pills, and the technique can even distinguish name-brand and generic versions of the same drug. By providing a fast (60-minute), inexpensive ($33 USD), and easy-to-use tool for identifying substandard and falsified medicines, Disintegration Fingerprinting can play an important role in the fight against fake drugs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Award 2131428 from the National Science Foundation Division of Biological Infrastructure (William Grover, PI); Award 2133084 from the National Science Foundation Division of Civil, Mechanical and Manufacturing Innovation (William Grover, co-PI); and Award 2019362 from the National Science Foundation Division of Computing and Communication Foundations (William Grover, co-PI). Oscar Fajardo was supported by the California Medicine Scholars Program at UC Riverside.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at open.groverlab.org.
